Clinical Trials Directory

Trials / Unknown

UnknownNCT00616382

Treating the Resistant Patent Ductus Arteriosus (PDA)

New Therapeutic Approaches to the Resistant Patent Ductus Arteriosus (PDA) in Low Birth Weight Neonates

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
68 (estimated)
Sponsor
Shaare Zedek Medical Center · Academic / Other
Sex
All
Age
2 Days – 4 Weeks
Healthy volunteers
Accepted

Summary

Persistent postnatal ductal patency may have significant adverse hemodynamic effects, frequently necessitating therapeutic intervention in order to facilitate ductal closure. Medical therapy for patency of the ductus arteriosus is successful mediating ductal closure in approximately 70% of treated infants. In a recent study in our population, 17% of the babies showed no ductal response to the first course of treatment and 9.4% of our study infants eventually underwent surgical ligation of the ductus after failure of medical therapeutic closure.We propose to evaluate and compare two alternate therapeutic approaches to ductal closure in babies who do not respond to initial therapy.

Conditions

Interventions

TypeNameDescription
DRUGIndomethacinIV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
DRUGPentoxifyllineIV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been

Timeline

Start date
2008-03-01
Primary completion
2010-03-01
First posted
2008-02-15
Last updated
2008-02-15

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT00616382. Inclusion in this directory is not an endorsement.